Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies

Partnership will analyse m6A RNA modifications in patient samples to support development of STC‑15

STORM Therapeutics has entered a new collaboration with US‑based AlidaBio to accelerate the development of cancer therapies that target RNA modifications.

The partnership will combine STORM’s clinical expertise with AlidaBio’s next‑generation sequencing platforms to deepen understanding of how inhibiting the RNA‑modifying enzyme METTL3 affects cancer biology.

The agreement will see STORM use AlidaBio’s EpiPlex and EpiScout technologies to detect and measure…